Contrasting CureVac (NASDAQ:CVAC) and Innovation Pharmaceuticals (OTCMKTS:IPIX)

Innovation Pharmaceuticals (OTCMKTS:IPIX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Innovation Pharmaceuticals and CureVac’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovation Pharmaceuticals	N/A	N/A	N/A
CureVac	-422.66%	-57.18%	-38.60%

Earnings & Valuation

This table compares Innovation Pharmaceuticals and CureVac”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CureVac	$65.86 million	10.13	-$281.58 million	($1.33)	-2.24

Innovation Pharmaceuticals has higher earnings, but lower revenue than CureVac.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Innovation Pharmaceuticals and CureVac, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovation Pharmaceuticals	0	0	0	0	N/A
CureVac	0	3	1	0	2.25

CureVac has a consensus target price of $10.00, indicating a potential upside of 235.57%. Given CureVac’s higher possible upside, analysts clearly believe CureVac is more favorable than Innovation Pharmaceuticals.

Summary

CureVac beats Innovation Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.